Date: Nov 03, 2016 Source: Biospace (
click here to go to the source)
RADNOR, Pa., Nov. 3, 2016 /PRNewswire/ -- VWR (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers, announced today the acquisition of two companies, Reliable Biopharmaceutical and BioArra.
Reliable Biopharmaceutical, a manufacturer of high quality active pharmaceutical ingredients (APIs) and high purity ingredients (HPIs) such as cGMP excipients and advanced intermediates for the biopharmaceutical industry, enhances VWR's growing custom chemical and biochemical manufacturing portfolio. Reliable Biopharmaceutical offers highly-flexible, scalable and solution oriented production ranging from small batch clinical manufacturing to full scale commercial production. Based in St. Louis, Missouri and founded in 1968, Reliable Biopharmaceutical is a key supplier for many pharmaceutical, biopharmaceutical, diagnostic and cosmetic companies.
BioArra, a leading producer of U.S. origin serum-based products for use in research and production, strengthens our support to cellular science customers. Founded in 2008 and headquartered in Eagleville, Pennsylvania, BioArra produces semi-processed serum from various USDA approved supplier locations.
"BioArra and Reliable Biopharmaceutical greatly complement our previous acquisitions," said Manuel Brocke-Benz, President and CEO of VWR. "Aligned with our overall mergers and acquisitions strategy, these acquisitions continue to broaden our capabilities to provide value-added services and high quality products to our customers."
Financial details of this acquisition remain confidential.
VWR (NASDAQ: VWR), headquartered in Radnor, Pennsylvania, is the leading global independent provider of product and service solutions to laboratory and production customers. With sales in excess of $4.3 billion in 2015, VWR enables science for customers in the pharmaceutical, biotechnology, industrial, education, government and healthcare industries. With more than 160 years of experience, VWR has cultivated a value proposition delivering product choice, operational excellence and differentiated services to improve our customers' productivity from research to production. VWR's differentiated services provide innovative, flexible and customized solutions from scientific research services to custom-manufactured chemical blends. Our dedicated team of more than 9,300 associates is focused on supporting scientists, medical professionals and production engineers to achieve their goals.
For more information on VWR, please visit www.vwr.com.
Director, Corporate Communications
Phone: (484) 885-9338
John Sweeney, CFA
VP, Investor Relations